Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. by Swarbrick, Michael M & Havel, Peter J
UC Davis
UC Davis Previously Published Works
Title

















eScholarship.org Powered by the California Digital Library
University of California
METABOLIC SYNDROME AND RELATED DISORDERS
Volume 6, Number 2, 2008
© Mary Ann Liebert, Inc.
Pp. 87–102
DOI: 10.1089/met.2007.0029
Physiological, Pharmacological, and Nutritional Regulation
of Circulating Adiponectin Concentrations in Humans
Michael M. Swarbrick, Ph.D. 1 and Peter J. Havel, D.V.M., Ph.D.1
Abstract
Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis.
It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional
to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascu-
lar disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a
potential therapeutic target for the metabolic syndrome and diabetes.
This review summarizes current research regarding the regulation of circulating adiponectin concentra-
tions by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In
humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely propor-
tional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined pri-
marily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less
adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by
significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by
a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by in-
flammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consump-
tion increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences
adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in hu-
mans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of
pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor




ADIPOSE TISSUE IS now well recognized as an importantsource of hormones that influence body adiposity, glu-
cose homeostasis, inflammation, and cardiovascular dis-
ease.1,2 Due to its involvement in each of these physiolog-
ical processes, the adipocyte-derived hormone adiponectin
(also referred to as Acrp30, AdipoQ, apM1, and GBP28 in
initial reports)3–6 has been intensively studied. This review
will focus on the physiological, pharmacological, and nu-
tritional factors that influence circulating adiponectin con-
centrations, with an emphasis on studies conducted in 
humans.
Adiponectin is an Adipocyte-Specific Secreted Protein
Dysregulated in Obesity, Type 2 Diabetes, and
Cardiovascular Disease
Adiponectin mRNA is highly expressed in and is rela-
tively specific for mature adipocytes.3,4 The human
adiponectin gene encodes a 244 amino acid, 30 kDa secreted
protein, which contains a putative signal sequence, a colla-
gen-like domain, and a globular domain. Adiponectin shares
structural similarity with collagens VIII and X, tumor ne-
crosis factor alpha (TNF-), and complement factor C1q.
In plasma, adiponectin circulates at very high concentra-
tions for a hormone, usually in the range 3 to 30 g/mL.
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Adiponectin concentrations are decreased in a variety of hu-
man metabolic and cardiovascular disease states, including
obesity,7 type 2 diabetes mellitus,8 lipodystrophy,9 nonalco-
holic hepatic steatosis,10 essential hypertension,11 and coro-
nary artery disease.12 Low adiponectin levels precede the de-
velopment of insulin resistance13 and myocardial infarction14
in humans. Interestingly, adiponectin concentrations in-
crease with age15 and are elevated in type 1 diabetes.16
Adiponectin is detectable in cerebrospinal fluid (CSF), with
CSF concentrations in humans typically 0.1% of corre-
sponding plasma concentrations.17,18
Adiponectin Action in Peripheral Tissues
Adiponectin has insulin-sensitizing actions in the liver, and
lowers blood glucose levels in diabetic animals by improving
insulin-mediated suppression of gluconeogenesis.19 In liver
and skeletal muscle, adiponectin also improves glucose uti-
lization and stimulates fatty acid oxidation via a pathway that
involves AMP kinase (AMPK) and acetyl-CoA carboxylase
(ACC).20 Adiponectin also prevents TNF-–stimulated ex-
pression of adhesion molecules in cultured human endothelial
cells21 by inhibiting IKK phosphorylation and NF-B activa-
tion,22 and inhibits the transformation of macrophages into
foam cells.23 Together, these effects have been shown to pre-
vent plaque formation in apoE-deficient mice, a mouse model
of atherosclerosis.24,25 Adiponectin may also prevent excessive
cardiac remodeling following injury. In response to pressure
overload, adiponectin-deficient mice exhibit an exaggerated
hypertrophic response compared to wild-type mice.26 This re-
sponse is prevented by intravenous administration of an ade-
novirus expressing adiponectin prior to injury.27
Adiponectin’s diverse actions in these tissues are medi-
ated by its receptors, AdipoR1 and AdipoR2.28 In humans,
AdipoR1 is ubiquitously expressed, with highest levels of ex-
pression in heart and skeletal muscle; while AdipoR2 ex-
pression is more restricted to skeletal muscle and liver.28
Overexpression of each receptor in the livers of leptin-defi-
cient mice revealed their divergent functions: overexpression
of AdipoR1 increased AMPK phosphorylation and reduced
the expression of genes involved in hepatic gluconeogene-
sis; while overexpression of AdipoR2 increased peroxisome
proliferator-activated receptor alpha (PPAR-) mRNA and
reduced the expression of inflammatory cytokines and mark-
ers of oxidative stress.29 In this model, overexpression of ei-
ther receptor reduced hepatic triglyceride content. In addi-
tion to AdipoR1 and AdipoR2, adiponectin also binds to
T-cadherin, a receptor localized on vascular endothelium
and muscle cells.30 This interaction may underlie some anti-
atherogenic, vascular-protective actions of adiponectin.
Adiponectin may also have actions in the central nervous
system (CNS) to influence the control of body weight, al-
though its specific role is controversial.31 Adiponectin is de-
tectable in CSF, and its receptors are abundantly expressed
in hypothalamic areas that control food intake.18 In mice, al-
though central administration of adiponectin was initially
shown to reduce body weight by increasing energy expen-
diture,32 intravenous adiponectin treatment has been re-
cently found to increase feeding in mice by activating AMP
kinase in the hypothalamus.33 Further studies are needed to
better define the potential role of adiponectin in the CNS reg-
ulation of energy homeostasis.
Adiponectin Circulates as Multimers that Activate
Differential Signaling Pathways
Adiponectin’s biological effects depend upon the forma-
tion of multimeric complexes and may require proteolytic
cleavage. The formation of higher-order structures in plasma
is similar to other proteins with collagen-like domains, such
as complement factor C1q.34 Adiponectin’s basic unit con-
sists of a trimer, formed by interactions within the globular
domain and stabilized by a collagenous coiled-coil struc-
ture.6 These trimers associate by disulfide bonds to form
hexamers, dodecamers (12 subunits), and octadecamers (18
subunits).35,36 Trimeric, hexameric, and larger forms of
adiponectin are referred to as low, medium, and high mo-
lecular weight (LMW, MMW, HMW), respectively.37 Glob-
ular adiponectin, a fragment of human adiponectin that in-
cludes the C-terminal globular domain, has demonstrated
biological activity in some studies, but is present at a much
lower concentration than the other forms of adiponectin.38
Growing evidence indicates that HMW adiponectin is the
most active form with respect to insulin sensitivity. Type 2 di-
abetes is associated with a lower proportion of adiponectin in
the HMW form, and this ratio (termed SA) is improved by treat-
ment with antidiabetic thiazolidinediones (TZDs).39 Injection
of HMW, but not MMW, adiponectin reduced blood glucose
in adiponectin-deficient mice,39 and mutations in the
adiponectin gene that interfere with the assembly of HMW
adiponectin are associated with insulin resistance and type 2
diabetes in humans.37 Other forms of adiponectin may have
oligomer-specific functions, as LMW and globular adiponectin,
but not MMW or HMW, activate AMPK in rat skeletal mus-
cle.40,41 In monocytes, only the LMW form inhibits NF ac-
tivity and proinflammatory cytokine release,42 while HMW
and adiponectin may instead exert the opposite effect.43
Adiponectin Synthesis and Secretion
Circulating adiponectin concentrations are the end result of
a complex, highly regulated secretory pathway in
adipocytes.44 Adiponectin mRNA expression is enhanced by
a variety of adipogenic transcription factors, including PPAR-
,45 C/EBP,46 C/EBP,47 FOXO1, SIRT1,48 and by Sp1, which
is induced during adipogenesis.49 Studies of humans with
obesity, type 2 diabetes, or gestational diabetes have shown
dysregulation of adiponectin mRNA in human adipose tis-
sue,50–52 however, changes in adiponectin mRNA expression
do not always correspond to changes in plasma adiponectin
concentrations.53,54 This latter observation supports the in-
volvement of post-transcriptional and post-translational
mechanisms in the regulation of adiponectin production.
Prior to secretion, adiponectin undergoes extensive post-
translational modifications including hydroxylation of pro-
line and lysine residues and glycosylation of hydrox-
ylysines.55 These modifications are necessary for HMW
multimer formation56,57 and are therefore likely to determine
HMW-induced activation of hepatic AMPK and its effects to
stimulate fatty acid oxidation and reduce liver triglyceride
deposition.57 Type 2 diabetes is associated with reduced gly-
cosylation of adiponectin as well as lower concentrations of
HMW adiponectin in the circulation.57
The assembly of hexameric and HMW adiponectin from
trimers requires the formation of disulfide bonds, at Cys-36
of the human protein and Cys-39 in the murine equiva-
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lent.35,37,40 These disulfide bonds are crucial for the release
of intracellular adiponectin58 via a process known as thiol-
mediated protein retention.59 This process involves two en-
doplasmic reticulum chaperones, ERp44 and Ero1-L. ERp44
retains adiponectin within the cell, and Ero1-L competes
with adiponectin for binding to ERp44. Accordingly, in-
creasing the amount of ERp44 in a heterologous system (cul-
tured human embryonic kidney cells) dose-dependently re-
duced adiponectin secretion, while reducing ERp44 levels in
adipocytes increased adiponectin secretion. The in vivo rela-
tionships between these chaperones and circulating adiponectin
concentrations are likely to be complex, however, as levels
of ERp44 protein in adipose tissue were greater in female
mice relative to male mice, and higher in wild-type mice rel-
ative to ob/ob mice, both conditions under which ERp44 pro-
tein levels would be expected to be reduced.35,37 The specific
mechanisms by which adiponectin is assembled and secreted
are currently under investigation, and may yield new phar-
macological targets to increase adiponectin production.
Adiponectin may also exert negative feedback inhibition
of its own production, as adiponectin mRNA expression in
cultured adipocytes is suppressed by treatment with physi-
ological concentrations of adiponectin.60 This is likely to be
due to degradation of about half of the synthesized
adiponectin prior to secretion.45 In a similar manner, trans-
genic mice designed to overexpress adiponectin specifically
in adipose tissue actually displayed lower circulating
adiponectin levels relative to wild-type mice.60 To circum-
vent this problem, it was necessary for Combs and col-
leagues45 to use transgenic mice overexpressing a mutated
form of adiponectin in order to elevate circulating
adiponectin concentrations.
Circulating adiponectin concentrations may also be af-
fected by renal clearance, as adiponectin levels are elevated
in states characterized by impaired renal function, such as
macroalbuminuria61 and end-stage kidney disease.62,63
Role of Adipose Distribution and Adipocyte Size
Visceral adiposity is an important determinant of plasma
adiponectin concentrations in humans. Direct assessments of
visceral fat in humans have repeatedly shown an independent
and inverse relationship between visceral adiposity and plasma
adiponectin concentrations.15,64–66 While this relationship is not
well supported by analyses of adiponectin mRNA expres-
sion,51,67,68 in one study of 36 morbidly obese nondiabetic sub-
jects it was reported that adiponectin mRNA expression in vis-
ceral fat, but not in subcutaneous fat, was positively correlated
with the serum adiponectin level.69 This finding is supported
by the results of in vitro experiments in which adiponectin se-
cretion from omental, but not subcutaneous, adipocytes under
basal conditions was found to be reduced in obesity.7 In an-
other study, both insulin-stimulated and rosiglitazone-stimu-
lated adiponectin secretion were found to be significantly
higher in omental relative to subcutaneous adipocytes, al-
though basal adiponectin secretion did not differ between the
two depots.70 Studies of cultured human adipose tissue also
suggest that subcutaneous adipocytes do not make a major con-
tribution (10%) to interindividual variations in circulating
adiponectin and insulin sensitivity.71 The importance of the vis-
ceral depot in determining circulating adiponectin concentra-
tions is also supported by a recent study in mice.72
Adiponectin production may also be determined by
adipocyte size.73 Larger adipocytes are more insulin-resis-
tant,74 and one mechanism by which TZDs improve insulin
sensitivity is by increasing the number of small, insulin-sensi-
tive adipocytes, at the expense of large, insulin-resistant ones.75
TZDs also increase adiponectin secretion.76 Our laboratory has
reported data from in vitro experiments indicating a strong in-
verse relationship between adipocyte volume and adiponectin
secretion from isolated rat adipocytes.77 Although our results
are not consistent with recent data obtained from human 
subcutaneous adipocytes,78 due to their anatomical source, 
the contribution of subcutaneous adipocytes to circulating
adiponectin concentrations appears likely to be minor com-
pared with adipocytes in visceral depots.
Diurnal Variation of Circulating Adiponectin
Concentrations and Effects of Meals, Glucose, 
and Insulin
Adiponectin concentrations in plasma are fairly stable
throughout the day, exhibiting only a minor fluctuation
(20%) from the 24-hour mean, with levels declining mod-
estly during the night to a nadir in the early morning.79 This
diurnal variation appears to be greater in females than in
males,79,80 and may increase in amplitude following signifi-
cant weight loss.80,81 Diurnal changes in adiponectin con-
centrations may be related to meals, as a study of 110 sub-
jects found that adiponectin concentrations decreased by 6%
two hours after a 75 g glucose load and by 8% five hours af-
ter a high-fat mixed meal.82 Other studies have reported lit-
tle or no diurnal variation in adiponectin levels,8,83,84 and
have indicated that adiponectin concentrations are un-
changed after 72 hours of fasting,85 however some of these
studies may have been underpowered to detect such small
effects. In one study, a four-fold postprandial increase in
adiponectin in obese, but not in normal weight, subjects was
reported.86 In contrast, we have observed that plasma
adiponectin concentrations do not change in either normal-
weight or overweight/obese subjects over the course of a
day during which 3 meals accompanied by glucose-sweet-
ened beverages were consumed, despite large postprandial
increases of glucose and insulin (unpublished observations).
Consistent with these results, infusion of 200 mg/m2/min
glucose for 48 hours in normal weight, insulin-sensitive hu-
mans produced moderate increases of plasma glucose, in-
sulin, and leptin concentrations, but did not change circu-
lating adiponectin concentrations at all.87 Overall, the
diurnal variation in circulating adiponectin concentrations is
much less than that observed for leptin.88
Although a consistent inverse relationship between
plasma insulin and adiponectin concentrations has been
shown in cross-sectional studies,8,89 the effects of insulin
on adiponectin secretion and circulating adiponectin lev-
els reported in both in vivo and in vitro studies are incon-
sistent. Short-term elevations in insulin, such as those mea-
sured during a hyperinsulinemic-euglycemic clamp,
modestly lower circulating adiponectin concentrations,
particularly the HMW form,90 in human subjects.91–93
In type 1 diabetic patients, however, nearly two years 
of insulin replacement did not significantly increase
adiponectin concentrations.16 Inconsistent effects of insulin
on adiponectin synthesis have been observed in isolated
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cells: pulse-chase studies of 3T3-L1 adipocytes have shown
that supraphysiological concentrations of insulin (160 nM)
roughly doubled adiponectin secretion over two hours.94
This is supported by data from our laboratory indicating
that adiponectin secretion from isolated rat adipocytes was
increased by a 96-hour exposure to physiological insulin
concentrations, and that both insulin-stimulated glucose
utilization and adiponectin secretion were reduced in large
adipocytes from obese animals compared with smaller,
more insulin-sensitive adipocytes from nonobese rats.77
The effects of insulin on adiponectin secretion may be cell-
and time-dependent, however, as adiponectin secretion
from cultured human subcutaneous and omental
adipocytes was reportedly unaffected by 24 hours of 100
nM insulin treatment.70
Effects of Caloric Restriction and Weight Loss on
Circulating Adiponectin Concentrations
There is little consistent evidence to indicate that
adiponectin concentrations in humans are regulated by
short-term caloric restriction, prior to significant weight
loss. In obese women, consumption of a a very low calo-
rie diet (550 kcal/day) for three weeks reduced weight by
approximately 5% but did not change adiponectin con-
centrations.95 In men, similarly, adiponectin levels were
unchanged following consumption of an 800 kcal/day diet
for four days.96 We have observed a modest (10%) but
significant increase in serum adiponectin in normal-weight
women following consumption of a calorie-restricted (600
kcal/day) diet for one week; interestingly, the opposite ef-
fect (an 20% decrease of adiponectin) was observed in
men restricted to 800 kcal/day.97 One study of healthy nor-
mal-weight women restricted to 1000 to 1200 kcal/day for
four weeks showed a significant reduction in adiponectin
concentrations (16%), despite an average weight loss of 3.4
kg.98 Analogously, exercise does not produce changes in
circulating adiponectin concentrations independently of
weight loss.99–101
In contrast, longer-term caloric restriction producing sig-
nificant weight loss (8–9% of initial weight) has been re-
peatedly shown to increase adiponectin concentrations (re-
viewed recently in Imbeault101). Weight changes of this
magnitude usually result from either long-term caloric re-
striction or various forms of weight loss surgery. In these
studies, the increase in adiponectin concentration appears to
be more related to the amount of weight lost than the method
used.102 We and others have reported that increases in
adiponectin following weight loss are strongly and nega-
tively correlated with changes in body weight, body mass
index (BMI) and fat mass.103–107 The failure of some ade-
quately-powered studies to observe changes in adiponectin
concentrations after significant weight loss may be attribut-
able to a redistribution of adiponectin oligomers, towards
the higher molecular weight forms, that is not apparent when
the total adiponectin concentration is examined.108–110 We
have observed that although total adiponectin concentra-
tions were unchanged one month after Roux-en-Y gastric
bypass surgery, absolute concentrations of HMW
adiponectin and the proportion of HMW adiponectin were
increased.103 Notably, adiponectin levels are also elevated in
patients with anorexia nervosa.111–112
Regulation of Adiponectin by Peroxisome Proliferator-
Activated Receptors
Peroxisome proliferator-activated receptors alpha, delta
and gamma (PPAR-, - and -) are ligand-activated nuclear
receptors involved in the regulation of lipid and carbohy-
drate metabolism and adipogenesis.113 PPARs are thought
to function as sensors for dietary fatty acids and their meta-
bolic derivatives,114 and are also activated by synthetic li-
gands such as fibrates (PPAR-), GW501516 (PPAR-) and
TZDs (PPAR-). Both fibrates and TZDs increase adiponectin
concentrations in humans115–117 through an induction of
adiponectin mRNA in adipose tissue.76,118 These effects are
mediated through a functional peroxisome proliferator re-
sponse element in the proximal adiponectin promoter.119
Adipose-specific PPAR- knockout mice have reduced
plasma adiponectin concentrations.120
Of the dietary fatty acids, n-3 (or omega-3) polyunsatu-
rated fatty acids, such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), have received a great deal of
attention as prophylactic agents for cardiovascular disease
and insulin resistance.121 DHA is a ligand for both PPAR-
and -,122 and oxidized EPA is a potent regulator of PPAR-
.123 n-3 fatty acids readily undergo oxidation at ambient
temperatures, even in the absence of exogenous oxidizing
reagents. In rats, the addition of high levels of EPA/DHA as
part of a high-fat diet (15% of the 35% fat by weight) for five
weeks increased adiponectin concentrations by approxi-
mately 20 to 30%.124 In ob/ob mice, similarly, consumption
of EPA at 5% of diet by weight for four weeks reduced
adipocyte size and increased adiponectin concentrations.125
Coculture experiments, involving both 3T3-L1 adipocytes
and macrophages, have recently shown that the stimulatory
effects of EPA on adiponectin concentrations are likely to in-
volve inhibition of TNF- secretion from neighboring mac-
rophages rather than direct effects on adiponectin mRNA in
adipocytes.125 Interestingly, micromolar concentrations of
EPA have also been shown to induce PPAR-1 mRNA in iso-
lated human subcutaneous adipocytes,126 suggesting an ad-
ditional mechanism by with EPA could increase adiponectin
concentrations. In obese humans with the metabolic syn-
drome, Itoh et al.125 recently found that consumption of
1.8g/day of highly-purified EPA for three months increased
adiponectin concentrations by approximately 60%. The rela-
tionship between n-3 fatty acid intake and adiponectin con-
centrations is further supported by the observation that
plasma DHA levels, which are indicative of dietary DHA in-
take, are proportional to adiponectin concentrations in hu-
mans.127
Fish oil is rich in both EPA and DHA, and in rodents, di-
etary supplementation with fish oil improves insulin resis-
tance with up to a two-fold increase of adiponectin concen-
trations.128,129 This effect likely involves PPAR- rather than
PPAR-, as fish oil–mediated increases in plasma
adiponectin concentrations were prevented by pharmaco-
logical inhibition of PPAR-, and were still observed in
PPAR--null mice.129 In humans, while diets high in fish oil
or n-3 PUFAs themselves are associated with a reduced risk
of cardiovascular disease,130,131 studies have yet to conclu-
sively demonstrate that they increase adiponectin concen-
trations132 independently of weight loss.81 The constrasting
effects of EPA125 and fish oil81 on adiponectin concentrations
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in humans may be due to the use in the former study of
highly-purified EPA preparations or subjects with preexist-
ing metabolic syndrome components. However, the amounts
of EPA administered were similar in both studies. Further
investigation will be required to conclusively determine
whether dietary supplementation with fish oil/EPA/DHA
increases adiponectin concentrations in humans.
Another dietary fatty acid, conjugated linoleic acid (CLA),
has been intensively studied for its effects to reduce fat
mass,133 especially in mice.134 Dietary CLA is derived from
dairy products and ruminant meats, such as beef and lamb,
and when added to human diets, it has been shown to mod-
estly reduce adiposity.135 Studies in isolated rat adipocytes
have shown that CLA inhibits adiponectin production, pos-
sibly via reductions in adipocyte glucose utilization and
PPAR- mRNA expression.136
Regulation of Adiponectin by Other 
Pharmacological Agents
Treatment of hypertension by inhibition of the renin-an-
giotensin system, using either angiotensin converting en-
zyme (ACE) inhibitors or angiotensin type 1 receptor (AT1R)
blockers, concomitantly improves insulin sensitivity and re-
duces new-onset type 2 diabetes in humans.137 The insulin-
sensitizing effects of ACE inhibitors and AT1R blockers are
likely to involve adiponectin, as the low adiponectin con-
centrations observed in hypertensive patients11 are increased
by treatment with these compounds.138,139 There are several
potential mechanisms involved: angiotensin II inhibits dif-
ferentiation of adipocytes, via the AT1 receptor,140 and also
inhibits key elements of the insulin signaling pathway in cul-
tured smooth muscle cells.141 Accordingly, treatment of
obese rats with AT1R blockers not only increases adipocyte
differentiation but also reduces TNF- expression in adipose
tissue.142 AT1R blockers have also been shown to be partial
agonists of PPAR-,143,144 and their ability to increase
adiponectin concentrations may be, at least partially PPAR-
–dependent, as eprosartan, which does not activate PPAR-
, had no effect on adiponectin secretion from 3T3-L1
adipocytes.145 Interestingly, olmesartan, another AT1R
blocker, prevented decreases in circulating adiponectin lev-
els in genetically and diet-induced obese mice by reducing
oxidative stress in adipose tissue.146
Adiponectin secretion is also influenced by the endo-
cannabinoid system. Receptors for endocannabinoids are
present on human adipocytes,147,148 and treatment with the
CB1 antagonist, rimonabant, increases adiponectin mRNA
and protein in cultured mouse adipocytes.147 In human pa-
tients, rimonabant treatment not only reduces body weight
and waist circumference, but also increases adiponectin con-
centrations and HDL-cholesterol.149 Notably, the increases
in adiponectin concentrations are larger than would be ex-
pected from the magnitude of the reductions of body weight
and adiposity. Although it has been approved and is used
in treatment of the metabolic syndrome in 38 countries
worldwide, rimonabant has not been approved for use in the
U.S., due to concerns about psychiatric side effects (depres-
sion and suicidal thoughts) reported in some patients.
Adiponectin secretion in cultured adipocytes and in mice
is inhibited by treatment with valproic acid, an anticonvul-
sant agent used therapeutically for the treatment of
epilepsy.150 Common side effects of valproate treatment in
humans include obesity151 and insulin resistance.152 Valproic
acid inhibits adiponectin gene expression and decreases
plasma adiponectin levels in mice by reducing the amount
of C/EBP,150 an adipogenic transcription factor which stim-
ulates adiponectin transcription.46,153
Endocrine Influences on Adiponectin Concentrations
Adiponectin concentrations in rodents and humans are
sexually dimorphic, with higher concentrations observed in
females compared with males. This appears to be due to a
selective increase in the HMW oligomer of the hormone.35
These differences develop during puberty and are a result
of inhibition of adiponectin production by circulating an-
drogens.154 In mice, HMW adiponectin concentrations are
increased by castration and are decreased by testosterone re-
placement,155 and testosterone replacement therapy signifi-
cantly reduces adiponectin concentrations in hypogonadal
men.156 Studies in 3T3-L1 adipocytes indicate that testos-
terone-mediated decreases in adiponectin secretion are due
to enhanced intracellular retention of HMW adiponectin.155
Adiponectin concentrations are stable throughout the
menstrual cycle.157 During pregnancy, however, both
adiponectin mRNA expression and circulating adiponectin
concentrations decline during the third trimester158 and post-
partum159 when insulin sensitivity is reduced. This may be
a mechanism to ensure greater nutrient availability for the
developing fetus.160 Reduced adiponectin concentrations
during pregnancy do not appear to be attributable to central
fat accumulation and weight gain,159 rather, they are likely
to result from inhibition by prolactin, which decreases
adiponectin content and secretion in cultured human
adipocytes and adipose tissue.159,161 Human adipocytes ex-
press prolactin receptors,159,162 and elevated prolactin levels
in humans have been associated with insulin resistance.163
Support for this inverse relationship has also been obtained
in mice: female, but not male, transgenic mice overexpress-
ing prolactin have reduced adiponectin levels.161 Interest-
ingly, adiponectin concentrations are not increased in pro-
lactin receptor–knockout mice,161 suggesting that this
particular pathway may exist to favor the suppression of
adiponectin, and thereby ensure fetal growth and develop-
ment.
Adiponectin mRNA expression and secretion in human
adipocytes are also inhibited by glucocorticoids.164 In
healthy subjects, similarly, acute intravenous administration
of 25 mg hydrocortisone transiently decreased adiponectin
by approximately 25% after one hour.165 This effect may be
dose-dependent, however, as no changes of adiponectin
were observed in men treated for 5 days with 3 mg dexam-
ethasone.166 Excessive endogenous glucocorticoid produc-
tion (Cushing disease) is associated with central obesity and
insulin resistance, conditions under which adiponectin con-
centrations would already be expected to be reduced. How-
ever, at the present time, there are no convincing data to sug-
gest that adiponectin levels are reduced in Cushing patients,
independently of obesity.165 In fact, Libè et al.167 reported
that there were no differences in adiponectin concentrations
between normal-weight Cushing patients and BMI-matched
control subjects with similar levels of insulin resistance, and
adiponectin concentrations did not change after treatment of
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the disease with transsphenoidal resection of the pituitary
adenomas.
The discrepant effects of glucocorticoids on adiponectin
observed between in vivo and in vitro studies might possibly
be resolved by considering the effects of intracellular steroid
metabolism, which appears to be an important determinant
of glucocorticoid action. 11 hydroxysteroid dehydrogenase
type 1 (11 HSD-1) regulates intracellular glucocorticoid lev-
els by converting inactive cortisone to active cortisol, and 
its activity is elevated in subcutaneous adipose tissue 
from obese subjects.168 11 HSD-1 may indirectly regulate
adiponectin gene transcription, as adipose-specific overex-
pression of this enzyme in transgenic mice decreased
adiponectin mRNA in mesenteric adipose tissue.169 Con-
versely, knockout of 11 HSD-1 in all tissues was associated
with increased adiponectin mRNA expression in epididymal
fat, although not in visceral mesenteric fat.170 Plasma
adiponectin concentrations were not measured in either of
these mouse studies, however, so the contribution of local
glucocorticoid action in regulating circulating adiponectin
concentrations remains to be determined.
Adiponectin may also be inhibited by growth hormone
(GH). Adiponectin secretion in cultured explants of human
adipose tissue is reduced by incubation with GH, and GH-
overexpressing transgenic mice of both sexes have lower cir-
culating adiponectin concentrations than wild-type litter-
mates.161 This effect appears to be independent of energy
balance and adiposity, as GH-overexpressing transgenic
mice have reduced body fat and are resistant to diet-induced
weight gain on a high-fat diet,171 conditions when circulat-
ing adiponectin concentrations would be expected to be el-
evated. The inverse relationship between GH and
adiponectin in mice is further supported by the observation
that GH receptor deficiency is associated with increased
adiponectin concentrations in both sexes.161 The underlying
mechanism has been recently shown to involve GH-medi-
ated increases in the expression of the p85 subunit of phos-
phatidylinositol 3-kinase (PI3K), a negative regulator of in-
sulin signaling, in adipose tissue.172 In humans, however,
there is presently a lack of consensus on whether elevated
GH levels (such as in acromegaly) are associated with re-
duced adiponectin concentrations.173–176 There is one posi-
tive report, however, of patients with acromegaly having low
adiponectin levels that were reversed following GH-lower-
ing therapy.177 However, treatment of HIV-associated
lipodystropy patients with recombinant human GH in-
creased circulating adiponectin by approximately 20% and
the increase of adiponectin was correlated with increases of
HDL cholesterol.178
Adiponectin synthesis and secretion also appear to be in-
hibited by activation of the sympathetic nervous system.
Adiponectin gene expression in human visceral adipose tis-
sue is inhibited by -adrenergic agonists.179 Similarly, in both
mouse adipose tissue explants and in vivo, -adrenergic ago-
nists reduce adiponectin mRNA, secretion and plasma con-
centrations, with 3-agonists having the greatest effect.179
Consistent with these findings, six months of treatment with
rilmenidine, which reduces the firing rate of sympathetic neu-
rons, increased adiponectin concentrations by approximately
35% in hypertensive human subjects, independently of
changes in weight or visceral adiposity.180 In contrast, stud-
ies examining adiponectin concentrations in response to cold
exposure-mediated activation of the sympathetic nervous sys-
tem have been much less consistent: one study in humans sug-
gests that cold exposure at 10°C decreases adiponectin 
concentrations after 90 minutes,101 while studies in rodents
have reported increases,181 decreases,182 and no change183 in
adiponectin mRNA or circulating concentrations in response
to cold exposure (18–24 hours at 4–6°C). These discrepancies
may reflect the different timepoints studied or species differ-
ences in responses to cold exposure.
Finally, a role for bone-derived hormones in the regula-
tion of insulin sensitivity has been suggested by the recent
observation that mice deficient in osteocalcin, a hormone se-
creted by osteoblasts, exhibit glucose intolerance and insulin
resistance, likely due to reduced adiponectin concentra-
tions.184 The influence of such osteogenic factors on glucose
homeostasis is likely to be an active area of future research.
Together, these observations indicate that during periods
of growth, stress, reproduction (and male sexual develop-
ment), a number of endocrine systems may act to decrease
circulating adiponectin concentrations, potentially increas-
ing nutrient availability via a transient reduction in insulin
sensitivity. Prolonged suppression of adiponectin produc-
tion, however, as occurs in response to visceral adipocyte hy-
pertrophy associated with weight gain, may prove mal-
adaptive and lead to the development of insulin resistance
and type 2 diabetes in susceptible individuals.
Effects of Inflammation and Oxidative Stress
In humans and in laboratory animals, obesity is frequently
characterized by macrophage infiltration into adipose tissue,
resulting in chronic, low-grade inflammation.185–187 This in-
flammatory state, characterized by elevated adipose tissue
TNF- expression188–189 and circulating concentrations of C-
reactive protein (CRP),190 interleukin-6 (IL-6),191 and mono-
cyte chemoattractant protein-1 (MCP-1),192 has been impli-
cated in development of many of the complications of severe
obesity, in particular, atherosclerosis, insulin resistance, and
type 2 diabetes.193 Cross-sectional studies have consistently
demonstrated an inverse relationship between adiponectin
concentrations and those of inflammatory markers such as
CRP, TNF-, and IL-6 .194,195
The inverse relationship between adiponectin and in-
flammation is well supported by in vitro data, as TNF-,164,196
IL-6,197 and CRP,198 inhibit adiponectin synthesis in human
and murine adipocytes. These inflammatory factors have all
been shown to interfere with insulin signaling in adipocytes,
reinforcing the idea that adiponectin secretion is likely to be
determined by adipocyte insulin sensitivity. TNF- induces
serine phosphorylation of insulin receptor substrate-1 (IRS-
1), which inhibits insulin receptor kinase activity and down-
stream signaling via PI3K activation.199 Inhibition of
adiponectin mRNA by CRP is also at least partially depen-
dent upon the PI3K pathway.198 Both IL-6 and TNF- reduce
the expression of IRS-1, GLUT-4, and PPAR- in 3T3-L1
adipocytes.200 Furthermore, IL-6 induces the expression of
suppressor of cytokine signaling (SOCS) proteins, which in-
hibit insulin signaling by binding to the insulin receptor and
IRS-1.201,202 Lastly, interleukin-15, an anabolic cytokine pro-
duced by skeletal muscle, increases adiponectin secretion
from 3T3-L1 adipocytes, suggesting the involvement of mus-
cle-to-adipocyte endocrine signaling.203
SWARBRICK AND HAVEL92
There are abundant data from studies in mice to indicate
that oxidative stress also regulates adiponectin secretion. Ox-
idative stress is defined as a persistent imbalance between
the production of highly reactive molecular species (chiefly
oxygen and nitrogen) and the capacity of antioxidant defense
systems to inactivate or remove them.204 Oxidative stress is
elevated in human obesity and insulin resistance.205 Results
obtained from experiments in mice suggest that lipid accu-
mulation in adipocytes, and a concomitant rise in ROS pro-
duction, may be a key trigger for the development of insulin
resistance via reduced adiponectin secretion.206 Exposure of
cultured primary rat adipocytes to hyperglycemic conditions
(15 mM glucose, 100 nM insulin) increases intracellular nu-
trient availability and ROS production, leading to a reduc-
tion in insulin sensitivity.207 Similarly, exposure of 3T3-L1
adipocytes to hydrogen peroxide, a powerful oxidizing
agent, reduces adiponectin mRNA expression within 10 
minutes.208 The mechanism(s) linking ROS production to
adiponectin secretion are currently under investigation, and
studies in 3T3-L1 adipocytes have suggested roles for un-
coupling protein-2 (UCP2), a protein which increases mito-
chondrial respiration, as well as the transcription factor
CHOP-10, which interferes with the C/EBP-binding region
in the promoter of the adiponectin gene.209
Cigarette smoking also reduces adiponectin concentra-
tions.210–212 Acute exposure to cigarette smoke significantly
reduced adiponectin levels by 9% after 3 hours, and the max-
imum decrease (15%) was observed after 12 hours.211 There
is some in vitro evidence to suggest that smoking suppresses
adiponectin secretion, either via generation of ROS or by di-
rect effects of nicotine on adipocytes,211 but this may also be
due to smoking-related inflammation,213 tissue hypoxia,214
or possibly via activation of the sympathetic nervous system
activity via nicotinic receptors in sympathetic ganglia.179 The
inhibitory effects of smoking on adiponectin contrast unfa-
vorably with those of alcohol consumption, as several stud-
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FIG. 1. Summary of factors that regulate adiponectin concentrations in humans. Factors with limited or conflicting data
in humans (including extended-release niacin222 and 13-cis-retinoic acid223) are indicated with a question mark.
ies have shown that adiponectin concentrations are increased
by moderate alcohol consumption.215,217
Conclusions
In the decade since its discovery, the adipocyte-derived
hormone adiponectin has been revealed to be a key compo-
nent in the relationships between excess adiposity, insulin
resistance, inflammation and cardiovascular disease. De-
creased adiponectin production by adipocytes, leading to re-
duced circulating adiponectin levels, is likely to be an im-
portant mechanism by which visceral adipose deposition
and a number of other hormones promote insulin resistance
in extra-adipose tissues, such as liver and skeletal muscle
(Figure 1). Adiponectin concentrations are reduced in obe-
sity, pregnancy, inflammation, and states of metabolic and
oxidative stress, while adiponectin levels are increased fol-
lowing weight loss and in anorexia nervosa. Collectively,
these observations can be drawn together by the recent pro-
posal that increases of adiponectin may act as a systemic
“starvation signal”218 indicating the availability of excess
storage capacity in adipocytes.219 As discussed by Behre,218
in starvation the presence of high adiponectin concentrations
in concert with reduced insulin-stimulated glucose up-
take.112 would act to increase lipid oxidation in liver and
muscle, limiting the use of amino acids as a source of energy
and sparing carbohydrate (glucose) for use by the CNS. As
a consequence of its actions to promote lipid metabolism as
an energy source, adiponectin is able to prevent the ectopic
deposition of triglyceride in liver and skeletal muscle, which
can occur in obesity and is associated with the development
of insulin resistance in these tissues.220,221 The “starvation
signal” hypothesis is further supported by data indicating
that adiponectin can stimulate food intake in mice by en-
hancing hypothalamic AMP kinase activity,33 however the
question of whether adiponectin has physiological actions
within the CNS is still controversial. Nonetheless, strategies
directed at increasing adiponectin production and its circu-
lating concentrations, whether by lifestyle interventions (diet
and weight loss), pharmacological therapy, or possibly with
nutritional supplements, will likely be effective approaches
for the prevention and treatment of insulin resistance/meta-
bolic syndrome, type 2 diabetes, and cardiovascular disease,
diseases that are rapidly increasing in prevalence worldwide.
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